Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...
NDAQ:ATOS) Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 ...
Atossa Therapeutics, Inc. has provided a shareholder update highlighting significant progress in their clinical programs, particularly with their therapy (Z)-endoxifen for breast cancer prevention ...
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company ...
Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results